查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1433662

In vivo CRO 市場規模、佔有率和趨勢分析報告：按模型類型、模式、適應症、GLP 類型、地區和細分市場進行預測，2024-2030 年

In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type (Non GLP, GLP Toxicology), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 257 Pages | 商品交期: 2-10個工作天內

價格

In vivo CRO 市場成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球體內CRO市場規模將達到79.3億美元，預測期內複合年成長率為8.1%。

新興國家醫藥市場的成長、對多種體內細胞療法的強勁需求、材料科學的快速發展以及藥物-器械組合的複雜性正在推動該地區的服務需求。此外，體內臨床前和臨床研究的增加、監管部門的核准、市場參與企業服務的擴展以及各種疾病負擔都對市場收益做出了貢獻。此外，新興經濟體增加低成本臨床前和臨床服務外包是支持體內 CRO 市場成長的關鍵因素之一。

同樣，越來越多的藥品境外外包到新興經濟體也創造了​​巨大的市場需求。已開發國家的預算審查、價格壓力和報銷制度的變化是預計印度和中國等新興國家藥品贊助商更多採用成本控制措施的一些關鍵因素。在新興國家，將臨床前體內服務等開發服務外包給合約服務供應商預計將增加對品質保證和監管服務的需求，從而促進對體內外包服務的需求增加。 FDA核准的嚴格流程以及歐盟地區的監管變化預計將使歐洲的核准流程複雜化。這些都是促使製藥公司境外外包到新興國家的主要因素。

COVID-19 大流行最初對臨床試驗行業產生了負面影響，但體內 CRO 市場也受到了負面影響。生物製藥產業將重點轉向開發針對 COVID-19 的疫苗和治療方法，這產生了意想不到的後果，可能會擾亂其他疾病的臨床試驗。細胞和基因治療行業的公司面臨的主要挑戰之一是無法在所需的臨床試驗地點及時為患者提供治療。此外，基於細胞的療法的提供在大流行後帶來了一些挑戰。由於擔心 SARS-CoV-2 傳播，尤其是針對弱勢群體，醫院對提供細胞治療服務猶豫不決。由於封鎖和旅行禁令，患者無法前往細胞治療中心。

此外，主要參與企業正在參與併購、合作夥伴關係、協議、聯盟和服務推出等策略，以擴大其全球足跡和服務/產品系列。例如，2023年4月，PsychoGenics, Inc.宣布推出eCube，這是一個藥理學腦電圖平台，旨在增強表現型藥物發現。同樣，2023年2月，百奧賽圖宣布推出Nano 100計劃，開發100多種針對特定標靶的全人奈米抗體藥物。這項工作將百奧賽圖專有的 RenNano（一種能夠產生完全人類奈米抗體的小鼠模型）與先進的體外和體內抗體篩檢平台結合。透過利用這些整合技術，百奧賽圖有望促進全人奈米抗體藥物的廣泛開發。

in vivo CRO 市場報告亮點

  • 由於囓齒類動物在基因上與人類相似，因此對模型的需求持續不斷，其中囓齒類動物細分市場佔據了最大的銷售佔有率，達到 81.8%。此外，它們體型小、生命週期短、易於維護和遺傳資源豐富，使其成為體內 CRO 研究最受歡迎的動物物種。
  • 小分子領域在體內 CRO 市場中佔據主導地位。這種成長是由候選藥物開發中對小分子的需求所推動的。此外，小劑量小分子的高治療功效正在推動這一領域的成長。
  • 2023年癌症領域的市場規模將是壓倒性的巨大，主要成長因素包括癌症負擔的增加、對新型基因療法的需求迅速增加以及癌症免疫療法的臨床前試驗。根據美國基因與細胞治療協會的數據，大約 97% 的 CAR T 細胞療法正在針對癌症適應症進行開發。
  • 由於各種針對腦部疾病的模型為基礎的臨床實驗藥物的功效，中樞神經系統疾病領域預計將出現最快的成長。
  • 由於根據特定指南進行的標準化測試的增加，GLP毒理學領域在2023年佔據了最大的市場佔有率。
  • 2023年，北美在vivo CRO市場中佔據最大收益佔有率，達到50.0%。該地區的成長歸因於成熟市場參與者的存在、各種疾病負擔的增加以及該地區對 CRO 的需求不斷成長。其他成長要素包括研發活動、臨床前試驗和市場參與者創新的增加。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章體內 CRO 市場：變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • in vivo CRO市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 價格分析

第4章體內CRO市場：模型類型估算及趨勢分析

  • 車型類型市場佔有率，2023 年和 2030 年
  • 細分儀表板
  • 按模型類型分類的全球體內 CRO 市場前景
  • 2018年至2030年市場規模、預測與趨勢分析

第5章 In vivo CRO市場：模態估計與趨勢分析

  • 2023年及2030年醫療器材市場佔有率
  • 細分儀表板
  • 按模式分類的全球體內 CRO 市場前景
  • 2018年至2030年市場規模、預測與趨勢分析

第6章 Invivo CRO市場：適應症估計與趨勢分析

  • 2023年及2030年指示市場佔有率
  • 細分儀表板
  • 按適應症分類的全球體內 CRO 市場前景
  • 2018年至2030年市場規模、預測與趨勢分析

第7章體內CRO市場：GLP類型估算及趨勢分析

  • 2023年及2030年GLP類型市場佔有率
  • 細分儀表板
  • 以 GLP 類型分類的全球體內 CRO 市場前景
  • 2018年至2030年市場規模、預測與趨勢分析

第8章體內CRO市場：區域估算與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商形勢
    • IQVIA Inc.
    • Crown Bioscience
    • Taconic Biosciences, Inc.
    • PsychoGenics Inc.
    • Evotec
    • Janvier Labs
    • Biocytogen Boston Corp
    • GemPharmatech
    • Charles River Laboratories
    • Icon Plc
    • Labcorp Drug Development
    • Parexel International Corporation
    • SMO Clinical Research（I）Pvt Ltd.
Product Code: GVR-1-68038-011-8

In Vivo CRO Market Growth & Trends:

The global in vivo CRO market size is expected to reach USD 7.93 billion by 2030, registering a CAGR of 8.1% during the forecast period, according to a new report by Grand View Research, Inc. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.

Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.

The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different! The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.

Furthermore, the key participants are engaged in strategies such as mergers & acquisitions, partnerships, agreements, collaborations, and service launches, among others, to expand their global footprints and service/product portfolio. For instance, in April 2023, PsychoGenics, Inc. announced the launch of eCube, a pharmaco-electroencephalography platform, to enhance phenotypic drug discovery. Similarly, in February 2023, Biocytogen recently introduced "the Nano 100 Project" to develop over 100 fully human nanobody drugs that target specific targets. This endeavor involves combining Biocytogen's proprietary RenNano, a mouse model capable of producing fully human nanobodies, with their advanced in vitro and in vivo antibody screening platforms. By leveraging these integrated technologies, Biocytogen is poised to facilitate the extensive development of fully human nanobody drugs.

In Vivo CRO Market Report Highlights:

  • The rodent-based segment held the largest revenue share of 81.8% owing to constant model demand as they are genetically similar to humans. Besides, their small size, short life cycle, ease of maintenance, and availability of genetic resources, make them the most prevalent species in in-vivo CRO research
  • The small molecule segment dominated the in vivo CRO market. The growth is attributed to the demand for small molecules in the development of drug candidates. In addition, the strong therapeutic effect of small molecules in a small dose is the key factor aiding segment growth
  • The oncology segment dominated the market in 2023, the key factors contributing to the growth include the growing burden of cancer, surging demand for new gene therapy, and preclinical studies for cancer immunotherapy. According to the American Society of Gene Cell Therapy, around 97% of CAR T-cell therapies are developed for cancer indications
  • The CNS conditions segment is anticipated to register the fastest growth, owing to the effectiveness of different model-based investigational compounds targeting brain diseases is expected to drive segment growth
  • The GLP toxicology segment accounted for the largest market share in 2023 owing to the increasing number of standardized studies conducted according to specific guidelines
  • North America held the largest revenue share of 50.0% in in-vivo CRO market in 2023. The growth in the region can be attributed to the presence of well-established market players, the increasing burden of different diseases, growing demand for CROs in the region. Other factors contributing to the growth are increased research and development activities, preclinical studies, and innovations of market players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Model Type
    • 1.2.2. Modality
    • 1.2.3. Indication
    • 1.2.4. GLP Type
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Model type outlook
    • 2.2.2. Modality outlook
    • 2.2.3. Indication outlook
    • 2.2.4. GLP type outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. In Vivo CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Changing regulatory landscape
      • 3.2.1.2. Increase in offshoring medical device manufacturing to emerging countries
      • 3.2.1.3. Rising demand for advanced products
      • 3.2.1.4. Implementation of international standards by contract manufacturers
      • 3.2.1.5. Rising price competition and requirement to reduce cost
      • 3.2.1.6. Increasing complexity concerning product design and engineering
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Compliance issues while outsourcing
      • 3.2.2.2. Changing scenarios in developing countries
      • 3.2.2.3. Regulatory and legal compliance
      • 3.2.2.4. Contractual obligation
  • 3.3. In Vivo CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. In Vivo CRO Market: Model Type Estimates & Trend Analysis

  • 4.1. Model Type Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global In Vivo CRO Market by Model Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Rodent based
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Rat models
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Mice models
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Others
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Non-rodent based
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. In Vivo CRO Market: Modality Estimates & Trend Analysis

  • 5.1. Modality Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global In Vivo CRO Market by Modality Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Small molecules
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Large molecules
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Cell & gene therapy
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.2. CAR T-cell therapies
      • 5.4.2.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.3. CAR-NK cell therapies
      • 5.4.2.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.4. TCR-T cell therapies
      • 5.4.2.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2.5. Other (Includes- TCR-NK, CARM, and TAC-T)
      • 5.4.2.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. RNA therapy
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis

  • 6.1. Indication Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global In Vivo CRO Market by Indication Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Oncology
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2. Blood cancer
      • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Solid tumor
      • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2. Solid tumor
      • 6.4.1.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2.2. Syngeneic model
      • 6.4.1.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2.3. Patient derived xenograft
      • 6.4.1.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.2.4. Xenograft
      • 6.4.1.3.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3.3. Others
      • 6.4.1.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. CNS conditions
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.2. Epilepsy
      • 6.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.3. Parkinson's disease
      • 6.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.4. Huntington's disease
      • 6.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.5. Stroke
      • 6.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.6. Muscular dystrophy
      • 6.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.7. Alzheimer's disease
      • 6.4.2.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.8. Traumatic brain injury
      • 6.4.2.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.9. Amyotrophic lateral sclerosis (ALS)
      • 6.4.2.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.10. Spinal muscular atrophy
      • 6.4.2.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.11. Muscle regeneration
      • 6.4.2.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.2.12. Other neurodevelopment disorders
      • 6.4.2.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Diabetes
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Obesity
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Pain management
      • 6.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.5.2. Chronic pain
      • 6.4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.5.3. Chronic pain
      • 6.4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Autoimmune/inflammation conditions
      • 6.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.6.2. Rheumatoid arthritis
      • 6.4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.6.3. Multiple sclerosis
      • 6.4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.6.4. Osteoarthritis
      • 6.4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.6.5. Irritable bowel syndrome
      • 6.4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.6.6. Others
      • 6.4.6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Others
      • 6.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis

  • 7.1. GLP Type Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global In Vivo CRO Market by GLP Type Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. GLP toxicology
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Non GLP
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. Mexico
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. IQVIA Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Crown Bioscience
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Taconic Biosciences, Inc.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. PsychoGenics Inc.
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Evotec
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Janvier Labs
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Biocytogen Boston Corp
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. GemPharmatech
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Charles River Laboratories
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Icon Plc
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
    • 9.3.14. Labcorp Drug Development
      • 9.3.14.1. Company overview
      • 9.3.14.2. Financial performance
      • 9.3.14.3. Product benchmarking
      • 9.3.14.4. Strategic initiatives
    • 9.3.15. Parexel International Corporation
      • 9.3.15.1. Company overview
      • 9.3.15.2. Financial performance
      • 9.3.15.3. Product benchmarking
      • 9.3.15.4. Strategic initiatives
    • 9.3.16. SMO Clinical Research (I) Pvt Ltd.
      • 9.3.16.1. Company overview
      • 9.3.16.2. Financial performance
      • 9.3.16.3. Product benchmarking
      • 9.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America in vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 4 North America in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 5 North America in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 6 North America in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 7 U.S. in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 8 U.S. in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 9 U.S. in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 10 U.S. in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 11 Canada in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 12 Canada in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 13 Canada in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Canada in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 15 Europe in vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 17 Europe in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 18 Europe in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 19 Europe in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 20 Germany in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 21 Germany in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 22 Germany in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 23 Germany in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 24 UK in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 25 UK in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 26 UK in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 27 UK in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 28 France in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 29 France in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 30 France in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 31 France in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 32 Italy in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 33 Italy in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 34 Italy in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 35 Italy in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 36 Spain in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 37 Spain in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 38 Spain in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 39 Spain in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 40 Denmark in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 41 Denmark in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 42 Denmark in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 43 Denmark in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 44 Sweden in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 45 Sweden in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 46 Sweden in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Sweden in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 48 Norway in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 49 Norway in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 50 Norway in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Norway in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific in vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 57 China in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 58 China in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 59 China in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 60 China in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 61 Japan in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 62 Japan in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 63 Japan in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 64 Japan in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 65 India in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 66 India in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 67 India in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 68 India in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 69 South Korea in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 70 South Korea in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 71 South Korea in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 72 South Korea in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 73 Australia in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 74 Australia in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 75 Australia in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 76 Australia in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 77 Thailand in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 78 Thailand in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 79 Thailand in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 80 Thailand in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 81 Latin America in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 82 Latin America in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 83 Latin America in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 84 Latin America in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 85 Brazil in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 86 Brazil in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 87 Brazil in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 88 Brazil in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 89 Mexico in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 90 Mexico in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 91 Mexico in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 92 Mexico in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 93 Argentina in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 94 Argentina in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 95 Argentina in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 96 Argentina in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 97 MEA in vivo CRO market, by region, 2018 - 2030 (USD Million)
  • Table 98 MEA in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 99 MEA in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 100 MEA in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 101 MEA in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 102 South Africa in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 103 South Africa in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 104 South Africa in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 105 South Africa in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 106 Saudi Arabia in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 110 UAE in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 111 UAE in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 112 UAE in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 113 UAE in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)
  • Table 114 Kuwait in vivo CRO market, by model type, 2018 - 2030 (USD Million)
  • Table 115 Kuwait in vivo CRO market, by modality, 2018 - 2030 (USD Million)
  • Table 116 Kuwait in vivo CRO market, by indication, 2018 - 2030 (USD Million)
  • Table 117 Kuwait in vivo CRO market, by GLP type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 In vivo CRO market: market outlook
  • Fig. 14 In vivo CRO competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 In vivo CRO market driver impact
  • Fig. 20 In vivo CRO market restraint impact
  • Fig. 21 In vivo CRO market strategic initiatives analysis
  • Fig. 22 In vivo CRO market: Model type movement analysis
  • Fig. 23 In vivo CRO market: Model type outlook and key takeaways
  • Fig. 24 Rodent based market estimates and forecast, 2018 - 2030
  • Fig. 25 Rat models estimates and forecast, 2018 - 2030
  • Fig. 26 Mice Models market estimates and forecast, 2018 - 2030
  • Fig. 27 Others estimates and forecast, 2018 - 2030
  • Fig. 28 Non-rodent based market estimates and forecast, 2018 - 2030
  • Fig. 29 In vivo CRO Market: Modality movement Analysis
  • Fig. 30 In vivo CRO market: Modality outlook and key takeaways
  • Fig. 31 Small molecules market estimates and forecasts, 2018 - 2030
  • Fig. 32 Large molecules market estimates and forecasts,2018 - 2030
  • Fig. 33 Cell & gene therapy market estimates and forecasts,2018 - 2030
  • Fig. 34 CAR T-cell therapies market estimates and forecasts, 2018 - 2030
  • Fig. 35 CAR-NK cell therapy market estimates and forecasts, 2018 - 2030
  • Fig. 36 TCR-T cell therapy market estimates and forecasts, 2018 - 2030
  • Fig. 37 Other (Includes- TCR-NK, CARM, and TAC-T) market estimates and forecasts, 2018 - 2030
  • Fig. 38 RNA therapy market estimates and forecasts, 2018 - 2030
  • Fig. 39 Others market estimates and forecasts, 2018 - 2030
  • Fig. 40 In vivo CRO market: Indication movement analysis
  • Fig. 41 In vivo CRO market: Indication outlook and key takeaways
  • Fig. 42 Oncology market estimates and forecasts, 2018 - 2030
  • Fig. 43 Blood cancer market estimates and forecasts,2018 - 2030
  • Fig. 44 Solid tumor market estimates and forecasts, 2018 - 2030
  • Fig. 45 Syngeneic model market estimates and forecasts,2018 - 2030
  • Fig. 46 Syngeneic model market estimates and forecasts, 2018 - 2030
  • Fig. 47 Xenograft market estimates and forecasts,2018 - 2030
  • Fig. 48 Others market estimates and forecasts,2018 - 2030
  • Fig. 49 CNS conditions market estimates and forecasts,2018 - 2030
  • Fig. 50 Epilepsy market estimates and forecasts,2018 - 2030
  • Fig. 51 Parkinson's disease market estimates and forecasts,2018 - 2030
  • Fig. 52 Huntington's disease market estimates and forecasts,2018 - 2030
  • Fig. 53 Stroke market estimates and forecasts,2018 - 2030
  • Fig. 54 Muscular dystrophy market estimates and forecasts,2018 - 2030
  • Fig. 55 Alzheimer's disease market estimates and forecasts,2018 - 2030
  • Fig. 56 Traumatic brain injury market estimates and forecasts,2018 - 2030
  • Fig. 57 Amyotrophic lateral sclerosis (ALS) market estimates and forecasts,2018 - 2030
  • Fig. 58 Spinal muscular atrophy market estimates and forecasts,2018 - 2030
  • Fig. 59 Muscle regeneration market estimates and forecasts,2018 - 2030
  • Fig. 60 Other neurodevelopment disorders market estimates and forecasts,2018 - 2030
  • Fig. 61 Diabetes market estimates and forecasts,2018 - 2030
  • Fig. 62 Obesity market estimates and forecasts,2018 - 2030
  • Fig. 63 Pain management market estimates and forecasts,2018 - 2030
  • Fig. 64 Chronic pain market estimates and forecasts,2018 - 2030
  • Fig. 65 Acute pain market estimates and forecasts,2018 - 2030
  • Fig. 66 Autoimmune/inflammation conditions market estimates and forecasts,2018 - 2030
  • Fig. 67 Rheumatoid arthritis market estimates and forecasts,2018 - 2030
  • Fig. 68 Multiple sclerosis market estimates and forecasts,2018 - 2030
  • Fig. 69 Osteoarthritis market estimates and forecasts,2018 - 2030
  • Fig. 70 Irritable bowel syndrome market estimates and forecasts,2018 - 2030
  • Fig. 71 Others market estimates and forecasts,2018 - 2030
  • Fig. 72 Others market estimates and forecasts,2018 - 2030
  • Fig. 73 Global in vivo CRO market: Regional movement analysis
  • Fig. 74 Global in vivo CRO market: Regional outlook and key takeaways
  • Fig. 75 Global in vivo CRO market share and leading players
  • Fig. 76 North America market share and leading players
  • Fig. 77 Europe market share and leading players
  • Fig. 78 Asia Pacific market share and leading players
  • Fig. 79 Latin America market share and leading players
  • Fig. 80 Middle East & Africa market share and leading players
  • Fig. 81 North America, by country
  • Fig. 82 North America
  • Fig. 83 North America market estimates and forecasts, 2018 - 2030
  • Fig. 84 U.S.
  • Fig. 85 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 86 Canada
  • Fig. 87 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 88 Europe
  • Fig. 89 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 90 UK
  • Fig. 91 UK market estimates and forecasts, 2018 - 2030
  • Fig. 92 Germany
  • Fig. 93 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 94 France
  • Fig. 95 France market estimates and forecasts, 2018 - 2030
  • Fig. 96 Italy
  • Fig. 97 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 98 Spain
  • Fig. 99 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 100 Denmark
  • Fig. 101 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 102 Sweden
  • Fig. 103 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 104 Norway
  • Fig. 105 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 106 Asia Pacific
  • Fig. 107 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 108 China
  • Fig. 109 China market estimates and forecasts, 2018 - 2030
  • Fig. 110 Japan
  • Fig. 111 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 112 India
  • Fig. 113 India market estimates and forecasts, 2018 - 2030
  • Fig. 114 Thailand
  • Fig. 115 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 116 South Korea
  • Fig. 117 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 118 Australia
  • Fig. 119 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 120 Latin America
  • Fig. 121 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 122 Brazil
  • Fig. 123 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 124 Mexico
  • Fig. 125 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 126 Argentina
  • Fig. 127 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 128 Middle East and Africa
  • Fig. 129 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 130 South Africa
  • Fig. 131 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 132 Saudi Arabia
  • Fig. 133 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 134 UAE
  • Fig. 135 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 136 Kuwait
  • Fig. 137 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 138 Market share of key market players- In vivo CRO market